書籍詳細

あ行 アテレクトミー

P.11 掲載の参考文献

• 1) Sterzer, S. H., Rosenblum, J., Show, R E. et al.: Coronary rotational ablation: initial experience in 302 procedures. J. Am. Coll. Cardiol. 21: 287-295, 1993

• 2) Popma, J. J., O' Neill, W. O., Kramer, B. et at.: A quantitative analysis of late angiographic outcome after transluminal extraction endarterectomy (TEC). Circulation 86: 1-457, 1992

• 3) Baim, D. S., Popma, J. J., Sharma, S. K et al.: Final results in the balloon vs. optimal atherectomy trial (BOAT): 6month angiography and 1 year clinical follow-up. Circulation 94: 1436, 1996

• 4) Topol, E. J., Leya, F, Pinkerton, C. A. et al.: A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. N. Engl. J. Med. 329: 221-227, 1993
  pubmed

• 5) Popma, J. J., Baim, D. S., Kuntz, R. E. et aL: Early and late quantitative angiographic outcomes in the optimal atherectomy restenosis study (OARS). J. Am. Coll. Cardiol. 27: 291A 1996

• 6) Suzuki, T., Kato, O., Fujita, T. et al.: Initial and long-term results of the adjunctive balloon angioplasty following coronary atherectomy study (ABACAS). J. Am. Coll. Cardiol. 29: 68A, 1997

P.13 掲載の参考文献

• 1) Ghiselli, G., Schaefer, E. J., Gascon, P. et al.: Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. Science 214: 1239-1241, 1981
  pubmed

• 2) Schaefer, E. J., Grigg, R. E. Ghiselli, G. et al.: Familial apolipoprotein E deficiency. J. Clin. Invest. 78: 1206-1219, 1986

• 3) Cladaras, C., Hadzopoulon-Cladaras, M., Felber, B. K. et al.: The molecular basis of a familial apo E deficiency. An acceptor splice site mutation in the third intron of the deficiency apo E gene. J. Biol. Chem. 262: 2310-2315, 1987

• 4) Mabuchi, H., Itoh, H., Takeda, M. et al.: Ayoung type III hyperlipoproteinemic patient associated with apolipoprotein E deficiency. Metabolism 238: 115- 119, 1989

• 5) Kurosaka, D., Teramoto, T, Mastushita, T et al.: Apolipoprotein E deficiency with a depressed mRNA of normal siZe. Atherosclerosis 88: 15-20, 1991

P.15 掲載の参考文献

• 1) Yoshimura, M., Yasue, H., Nakayama, M. et al.: A missense Glu298Asp variaaant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Human Genetics, 1998 (in press)

• 2) Shimasaki, Y., Yasue, H., Yoshimura, M. et al.: Association of the missense Glu298Asp mutation in the endothelial nitric oxide synthase gene with myocardial infarction in the Japanese J. Am. Coll. Cordiol., 1506-1510, 1998

• 3) Miyamoto, Y., Saito, Y, Kajiyama, N. et al.: Endothothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension, 1998 (in press)

P.17 掲載の参考文献

• 1) Conner, W. E. and Conner, S. L.: Are fish oils benefical in the prevention and treatment of coronary artery disease？ Am. J. Clin. Nutr. 66 (suppl.): S1020-S1031, 1997

• 2) 熊谷朗: EPAの医学. 疫学・栄養学から臨床応用まで, 中山書店, 東京, 1994

• 3) Kang, J. K and Leaf, A Antiarrhythmic effect of polyunsatUrated fatty acids, recent studies (review). Circulation 94: 1774-1780, 1996

• 4) 浜崎智仁: n-3系高度多価不飽和脂肪酸よりみた脂肪の選択栄養. 評価と治療 14: 263-270, 1997

P.19 掲載の参考文献

• 1) Frick, M. H., Elo, O., Haapa, K. et al.: Helsinki Heart Study primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N. Engl. J. Med. 317: 1237-1245, 1987
  pubmed

• 2) Shephered, J., Cobbe, S. M., Ford, I. et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333: 1301-1307, 1995

• 3) Gotto, A M.: 第70回アメリカ心臓協会発表. 1997 (オルランド)

P.21 掲載の参考文献

• 1) 中谷矩章: 薬物療法の理論と実践-陰イオン交換樹脂-. 臨床医 18: 419-422, 1992

• 2) 中谷矩章: 陰イオン交換樹脂. 循環系治療薬の作用メカニズム, 戸田昇, 安孫子保編, 南江堂, 東京, 1998, pp. 381-385

P.23 掲載の参考文献

• 1) 袴田秀樹, 堀内正公: ACAT遺伝子の調節機構. 分子リピドロジー, メジカルセンス, 東京, 1997, pp. 97-107

• 2) Chang, C. C., Hush, H. Y., Cadigan, K M. et al.: Molecular cloning and functional expression of human acylcoenzyme A: cholesterol acyltransferase cDNA in mutant chinese hamster ovary cells. J. Biol. Chem. 268: 20747-20755, 1993

• 3) 山下静也: ACAT. 循環器病キーワード. 羊土社, 東京, 1997, PP. 86-87

P.25 掲載の参考文献

• 1) 馬渕宏: 動脈硬化症のコレステロール低下療法- HMG-CoA還元酵素抑制剤による成果と将来展望-動脈硬化 25: 83, 1997

• 2) Endo, A, Kuroda, M. and Tsujita, Y: ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J. Antibiot. (Tokyo) 29: 1348, 1976

• 3) Roberts, W. C.: Editorial. The underused miracle drugs: the statin drugs are to atherosclerosis what penicillin was to infectious disease. Am. J. Cardiol. 78 : 377, 1996
  pubmed

P.27 掲載の参考文献

• 1) Sano, H., Higashi, T., Matsumoto, K et al.: Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of advanced glycation end products. J. Biol. Chem. 273: 8630-8637, 1998
  pubmed

• 2) 佐野裕之, 堀内正公: 糖尿病性細小血管症とAGE-糖尿病の最前線. 新臨床医のための分子医学シリーズ, 羊土社, 東京, 1997, pp. 140-154

• 3) Suzuki, H., Kurihara, Y, Takeya, M. et al.: A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386: 292-296, 1997
  pubmed

P.29 掲載の参考文献

• 1) Richard, T. L and Peter, T.: The unstable atheroma. Artenoscler. Thromb. Vase. Biol. 17: 1859-1867, 1997

• 2) 岡田明子, 清水元治: マトリックスメタロプロテアーゼと癌の浸潤・転移. 蛋白質核酸酵素 42: 2386-2392, 1997

• 3) 小山則行: 平滑筋細胞のマトリックスとインテグリン受容体の相互作用. 分子動脈硬化学, メディカルレビュー社, 大阪, 1995, pp. 205-212

P.31 掲載の参考文献

• 1) 山本誉, 谷叙孝: 高脂血症に対するLDL吸着 (基礎). 血液浄化法の基礎と臨床応用の進歩. Biomedical Perspectives 6: 247-253, 1997

• 2) 古賀伸彦, 佐藤隆: LDLアフェレシスによる動脈硬化の進展予防と安定化・退縮. 日本アフェレシス学会雑誌15: 293-302, 1996

• 3) 小嶋俊一: LDLアフェレシスと凝固因子. 日本アフェレシス学会雑誌 15: 275-281, 1996

P.33 掲載の参考文献

• 1) Brown, M. and Goldstein, J. L: Areceptor mediated pathway for cholesterol homeostasis. Science 232: 34-47, 1986

• 2) Goldstein, J. L, Hobbs, H. H. and Brown, M. S.: Familial hypercholesterolemia. In: The Metabolic and Molecular Basis of lnherited Diseases, ed. by Scriver et al., McGraw-Hill, NY, 1995, p. 1981

• 3) Ishibashi, S., Perrey, S., Zhong, C. et at.: Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. J. Biol. Chem. 271: 22422-22427, 1996

P.35 掲載の参考文献

• 1) Urayama, H., Ohtake, H., Yokoi, K et al.: Long-term results of endartectomy, anatomic bypass and extraanatomic bypass for aortoiliac occlusive disease. Surg. Today 28: 151-155, 1998

• 2) Abbott, W. M., Green, R M., Matsumoto, T. et al.: Prosthetic above-knee femoropopliteal bypass grafting: Results of a multicenter randomized prospective trial. J. Vasc. Surg. 25: 19-28, 1997

• 3) Gupta, A K, Bankyk, D. F., Cheanvechai, D. et aL: Natural history of infrainguinal vein graft stenosis relative to bypass grafting technique. J. Vasc. Surg. 25: 211-225, 1997

P.37 掲載の参考文献

• 1) 馬渕宏: 家族性高コレステロール血症. 南江堂, 東京, 1991

• 2) Goldstein. J. L, Hobbs. H. H. and Brown. M. S.: Familial hypercholesterolemia. ln: The Metabolic and Molecular Bases oflnherited Disease, ed. by Scriver, C. Ret al., McGraw-Hill, NY, 7th Ed., 1995, pp. 1981-2030

• 3) Hobbs, H. H., Brown, M. S. and Goldstein, J. L: Molecular genetics of the LDL receptor gene in familial hypercholester olemia. Hum. Mutat. 1: 445-466, 1992

• 4) Grossman, M., Rader, D. J., Muller, D. W. et al.: A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolemia. Nature Medicine 1: 1148-1154, 1995

P.41 掲載の参考文献

• 1) Lane, D. P.: p53, guardian of the genome. Nature 258: 15-16, 1992

• 2) Nevins, J. R: E2F: a link between the Rb tumor sup- pressor protein and viral oncoproteins. Science 258: 424-429, 1992

P.43 掲載の参考文献

• 1) Fuster, V., Badimou, L, Chesebro, J. H. et al.: The pathogenesis of coronary artery disease and the acute coronary syndrome. N. Engl. J Med. 326: 242- 250, 1992

• 2) The CAPTURE investigators: Randomized placebo-controlled trial of abximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 349: 1429-1435, 1997

• 3) Shepherd, J., Cobbe, S. M., Ford, I. et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333: 1301-1307, 1995
  pubmed

P.45 掲載の参考文献

• 1) RITA-2 trial participants.: Coronary angioplasty versus medical therapy for angina (RrTA-2). Lancet 350: 461-468, 1997

• 2) Yusuf, S., Zucker, D., Peduzzi, P. et al.: Effect of coro- nary artery bypass graft surgery on survival: over-view of 10-year results from randomised trials by the coronary artery bypass graft surgery trialists collaboration. Lancet 344: 563-570, 1994

• 3) Mohri, M., Koyanagi, M., Egashira, K et at.: Angina pectoris caused by coronary microvascular spasm. Lancet 351: 1165-1169, 1998 (in press)

P.51 掲載の参考文献

• 1) Doherty, T. M. and Detrano, R C.: Coronary arterial calcification as an active process: anew perspective on an old problem. Calczf Tissue Int. 54: 224-230, 1994

• 2) Demer, L L, Watson, K E. and Bostrom, K: Mechanism of calcification in atherosclerosis. Trentls Cardiovasc. Med. 4: 45-49, 1994
  pubmed

• 3) 塩井淳, 西沢良記, 城野修一ほか: 血管石灰化におけるオステオポンチンの発現とその調節. 動脈硬化 24: 547-550, 1997

P.53 掲載の参考文献

• 1) von Birgelen, C., Kutryk, M. B., Gil, R et al.: Quantification of the minimal luminal cross-sectional area after coronary stenting by tWo- and three-dimensional intravascular ultrasound versus edge detection and videodensitometry. Am. J. CardioL 78: 520-525, 1996

• 2) Birnbaum, Y., Fishbein, M. C., Luo, H. et al.: Regiopnal remodeling of atherosclerotic arteries: A major determinant of clinical manifestations of disease. J. Am. Coll. Ca rdioL 30: 1149-1164, 1997

P.57 掲載の参考文献

• 1) Dzau, V. J.: Vascular biology and medicine in the 1990s.: scope concepts potentials and perspectives. Circulation 87: 705-719, 1993
  pubmed

• 2) 伊藤裕, 中尾一和: 局所分泌系-血管内皮を中心に. 最新内科学体系2, 科学としての内科学, 中山書店, 東京, 1996, pp. 213-224

P.59 掲載の参考文献

• 1) 上野光: 遺伝子治療の基礎知識-アデノウイルスベクターの特徴とその応用. Diabetes Frontier 8: 217-222, 1997

• 2) Baek, S. and March, K L: Gene therapy for restenosis. Circ. Res. 82: 295-305, 1998
  pubmed

• 3) DeYoung, M. B. and Dichek, D. A: Gene therapy for restenosis. Circ. Res. 82: 306-313, 1998
  pubmed

P.61 掲載の参考文献

• 1) 丸山征郎: 血管機能とその検査. 日内会誌80: 839, 1991

• 2) Ross, R.: The pathogenesis of atherosclerosis: aperspective for the 1990s. Nature 362: 801-809, 19933) Fuster, V.: Human lesion stUdies. Ann. N. Y Acad. Sci. 811: 207-224, 1997

P.63 掲載の参考文献

• 1) Thomas, J. R., Jeffrey, L A, Elliott, M. A et al.: ACC/AHA Guidelines of the management of patients with acute myocardial infarction. JACC. 28: 1328-1428, 1996

• 2) Fibrinolytic Therapy Trialist: (FIT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative over- view of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343: 311-322, 1994

P.65 掲載の参考文献

• 1) The SiXth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch. Intern. Med. 157: 2413-2446, 1997
  pubmed

• 2) Estacio, R O., Jeffers, B. W., Hiatt, W. R. et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N. Engl. J. Med. 338: 645-652, 1998
  pubmed

• 3) Neaton, J. D. and Wentworth, D.: Serum cholestero1, blood pressure, cigarette smoking and death from coronary heart disease. Overall findings and differences by age for 316, 099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch. Intern. Med. 152: 56-64, 1992

P.67 掲載の参考文献

• 1) Reaven, G. M.: Banting lecture 1998;role of insulin resistance in human disease. Diabetes 37: 1595- 1607, 1998

• 2) Kaplan, N. M.: The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch. Intern. Med. 149: 1514-1520, 1989
  pubmed

• 3) Agata, J., Masuda, A, Takada, M. et al.: High plasma immunoreactive leptin level in essential hypertension. Am. J. Hypertens. 10: 1171-1174, 1997
  pubmed

• 4) Julius, S.: Coronary disease in hypertension: a new mosaic. J. Hypertens. 15 (supple. 2): S3-S10, 1997

P.69 掲載の参考文献

• 1) 松田保: 止血・血栓の臨床. 新興医学出版社, 東京, 1996

• 2) 松田保: DICの臨床. 新興医学出版社, 東京, 1997

P.71 掲載の参考文献

• 1) 山崎義光, 鎌田武信: 耐糖能障害と動脈硬化. 糖尿病学1997, 小坂樹徳, 赤沼安夫編, 診断と治療社, 東京, 1997, pp. 164-176

• 2) 柳澤克之, 牧田善二: 高血糖と動脈硬化. Modern Diabetes(2)糖尿病血管合併症の診断と治療, 河盛隆造, 柏木厚典, 門脇孝編, メジカルビュー社, 東京, 1997, pp. 190-197

• 3) 山崎義光: 血糖コントロールと大血管合併症. 糖尿病の療養指導: 97, 日本糖尿病学会編, 診断と治療社, 東京, 1997, pp. 164-167

P.73 掲載の参考文献

• 1) 近藤和雄, 岩本珠美: 脂質栄養学の最前線-脂質栄養と動脈硬化 . 日本油化学会誌46: 1195-1203, 1997

• 2) 近藤和雄, 板倉弘重: 酸化ストレスよりみた脂肪の選択. 栄養-評価と治療14: 271-275, 1997

• 3) 近藤和雄: 酸化LDLの抑制-食事療法を中心に-. 71herapeutic Research 18: 131-137, 1997

P.75 掲載の参考文献

• 1) 佐久間長彦, 野口善令, 日比野剛: 酸化ストレスへの対応: ビタミン・薬物. 日本老年医学会雑誌34: 729-732, 1997

• 2) Kita, T., Nagano, Y., Yokode, M. et al.: Probucol pre vents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA 84: 5928-5931, 1987

• 3) Gey, K E, Brubacher, G. and Stahelin, B.: Plasma levels of antioxidant vitamins in relation to ischemic heart disease and cancer. Am. J. Clin. Nutr. 45: 1368-1377, 1987

• 4) Bellizzi, M. C., Franklin, M. E, Dathie, G. G. et al.: Vitamin E and coronary heart disease. The European paradox. Eur. J. Clin. Nutr. 48: 822-831, 1994

P.81 掲載の参考文献

• 1) Blair, S. N., Kohl, H. W., Paffenbarger, R. S. Jr. et al.: Physical fitness and all-cause mortality. A prospective study on healthy men and women. JAIVL4262: 2395-2401, 1989
  pubmed

• 2) Matsuzawa, Y, Shimomura, I. and Nakamura, T.: Pathophysiology and pathogenesis of visceral fat obesity. Ann. N. M Acad. Sci. 748: 399-406, 1993

• 3) Sasaki, J., Tanabe, Y, Tanaka, H. et al.: Elevated levels of HDL2-cholesterol and apo A-1 in national class Japanease male marathon runners. Atherosclerosis 70 : 175-177, 1988

P.83 掲載の参考文献

• 1) Miyashita, Y., Shirai, K, Ito, Y. et aL: Cytotoxicity of some oxysterols on human vascular smooth muscle cells was mediated by apoptosis. J. Atheroscler. Thromb. 4: 73-78, 1997
  pubmed

• 2) Esabelle, E-B., Olivier, M., Anne, N-S. et al.: Oxidized LDLs induce massive apoptosis of cultured human endotherial cells through a calcium-dependent pathway: Prevention by aurintricarboxylic acid. Arteioscler. Thromb. Vasc. Biol. 17: 331-339, 1997

• 3) Evan, G. 1., Wyllie, A H., Gilbert, C. S. et al.: Induction of apoptosis in fibroblasts by c-myc protein. Cetl 69: 119-128, 1992

P.85 掲載の参考文献

• 1) Parums, D. V., Brown, D. L, Mitchinson, M. J. et al.: Serum antibodies to oxidized low density lipoprotein and ceroid in chronic periaonitis. Arch. Pa thol. Lab. Med. 114: 383-387, 1990

• 2) Shimada, M., Ishibashi, S., Inaba, T. et al.: Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Proc. Natl. Acad. Sci. USA. 93: 7242-7246, 1996
  pubmed

• 3) Murakami, T., Michelagnili, S., Renato, L et al.: Triglycerides are major determinant of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler. Thromb. Vasc. Biol. 15: 1819-1828, 1995

P.87 掲載の参考文献

• 1) 及川眞一: 高脂血症診断の進め方. 今月の治療6: 434-440, 1998

• 2) 近藤和雄, 平野玲子, 岩本珠美: 高脂血症から動脈硬化へ: 効果的な食事療法の進めかた. Medical Practice 14: 627-630, 1997

• 3) 中谷矩章: 高脂血症の治療の進歩: 食事・運動療法.内科81: 280-282, 1998

• 4) 多田紀夫: アテローマの形成-予防治療と効果: トリグリセライド,レムナント. Modern Physician 18: 53-56, 1998

P.89 掲載の参考文献

• 1) 野間昭夫: 高Lp (a) 血症の治療. リポ蛋白 (a) のすべて, 中外医学社, 東京, 1996, pp. 243-255

• 2) Berglind L B.: Diet and drug therapy for lipoprotein (a). Curr. Opin. Lipidol. 6: 48-56, 1995

• 3) Angelin, B.: Therapy for lowering lipoprotein (a) levels. Curr. Opin. Lipidol. 8: 337-341, 1997
  pubmed

P.91 掲載の参考文献

• 1) Hirano, K, Yamashita, S., Nakajima, N. et at.: Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene muta60n is not associated with longevity. Arterioscler. Thromb. Vasc. Biol. 17 : 1053-1059, 1997

• 2) Hirano, K, Yamashita, S., Kuga, Y et al.: Atherosclerotic disease in marked hyperalphalipoproteinemia: combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscter. Thromb. Vasc. Biol. 15: 1849-1856, 1995
  pubmed

P.95 掲載の参考文献

• 1) Hajjar, D. P.: Viral pathogenesis of atherosclerosis. Impact of molecular mimicry and viral genes. Am. J. Pathot. 139: 1195-1211, 1991

• 2) 米満吉和, 古森公浩, 居石克夫ほか: ヒト血管病変におけるサイトメガロウイルス感染とその意義. 日 本臨牀56: 102-108, 1998

• 3) Tanaka, S., Komori, K, Okadome, K. et al.: Detection of active cytomegalovirus infection in inflammatory aortic aneurysms with RNA polymerase chain reaction. J. Vasc. Surg. 20: 235-243, 1994
  pubmed

P.99 掲載の参考文献

• 1) Casscells, W.: Migration of smooth muscle and endothelial cells : critical events in restenosis. Circulation 86: 723-729, 1992
  pubmed

• 1) Gibbons, -G. H. and Dzau, V. J.: Molecular therapies for vascular diseases. Science 272 : 689-693, 1996
  pubmed

• 1) Anderson, W. D. and King, S. B. III: A review of randomized trials comparing coronary angioplasty and bypass grafting. Curr. Opin. Ca rdiol. 11 : 583-590, 1996

P.101 掲載の参考文献

• 1) Fridovich, I.: Superoxide anion radical (02°-), superoxide dismutases, and related matters. J. Biol. Chem. 272: 18515-18517, 1997

• 2) Steinberg, D.: Low density lipoprotein oxidation and its pathological sign近cance. J. Biol. Chem. 272: 20963-20966, 1997

• 3) Elinder, L S. and Walldius, G.: AntioXidants and atherosclerosis progression: unsolved questions. Curr. Opin. Lipidol. 5: 265-268, 1994

P.103 掲載の参考文献

• 1) The Bypass Angioplasty Revascularization Investigation Investigators: Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N. Engl. J. Med. 335: 217-225, 1996
  pubmed

• 2) CABRI TriaI Participants : First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularization Investigation). Lancet 346 : 1179- 1184, 1995

• 3) Calafiore, A. M., Angelini, G. D., Bergsland, J. et al.: Minimally invasive coronary artery bypass grafting. Ann. 71110rac. Surg. 62: 1545-1548, 1996
  pubmed

P.105 掲載の参考文献

• 1) 心臓血管系の力学と基礎計測. 講談社サイエンティフィック, 沖野遙, 菅原基晃, 松尾裕英編, 講談社, 東京, 1980

• 2) Jafirin, M. Y. and Caro, C. G.: Biological flows, Plenum press, NY, 1995

P.107 掲載の参考文献

• 1) Fuster, V., Badimon, L, Badimon, J. J. et aL: The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. J. Med. 326: 242-250, 310-318, 1992

• 2) van der Wal, A C., Becker, A E., van der Loos, C. M. et al.: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89: 36-44, 1994
  pubmed

• 3) Farb, A, Burke, A P., Tang, A L et al.: Coronary plaque erosion without ruptUre into a lipid core;A frequent cause of coronary thrombosis in sudden coronary death. Circulation 93: 1354-1363, 1996

• 4) Thiruvikraman, S. V., Guha, A, Roboz, J. et al.: In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab. Invest. 75: 451-461, 1996

P.109 掲載の参考文献

• 1) 吉田洋二: 動脈硬化発生のメカニズム. 臨床医のための動脈硬化症, 日本医師会編, 東京, 1992, pp.10-13

• 2) 春野明弘, 森崎信尋: 脂質沈着と内皮損傷のどちらが先か？. Medical Practice 14: 526-530, 1997
  Medical*Online

• 3) Fuster, V., Badimon, L, Badimon, J. J. et al.: The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. /. Med. 326: 242-250, 1992
  pubmed

• 4) Libby, P.: Molecular bases of the acute coronary syndromes. Circulation 91: 2844-2850, 1995
  pubmed

P.111 掲載の参考文献

• 1) Ross, R and Glomset, J. A: Atherosclerosis and the arterial smooth muscle cell. Science 180: 1322-1339, 1973

• 2) Ross, R: The pathogenesis of atherosclerosis- An update. N. Engl. J. Med. 314: 488-500, 1986
  pubmed

• 3) Ross, R.: The pathogenesis of atherosclerosis: aperspective for the 1990s. Natza re 362: 801-809, 1993

P.113 掲載の参考文献

• 1) 田中明: レムナントリポ蛋白と動脈硬化. Pharma Medica 13: 47-52, 1995
  Medical*Online

• 2) Nakajima, K, Okazaki, M., Tanaka, A. et al.: Separa- tion and detemlination of remnant-like particles in human serum using monoclonal antibodies to apo B100 and apo A-1. J. CIinical Ligand Assay 19: 177- 183, 1996

• 3) 田中明: 高レムナント血症, 診断に必要な知識. Prog. Med. 17: 260-265, 1997

P.115 掲載の参考文献

• 1) 中村治雄: 原発性高脂血症の疫学. 高脂血症-病態と治療, 垂井清一郎, 松沢佑次編, 厚生省特定疾患 「原発性高脂血症」調査研究班事務局, 1988

• 2) Urabe, M., Yamamoto, T., Honjo, H. et al.: Effect of estrogen replacement therapy on hepatic triglyceride lipase, lipoprotein lipase and lipids including apolipoprotein E in climacteric and elderly women. Endocrine J. 43: 737-742, 1996

• 3) Weiner, C. P., Lizasoain, I., Baylis, S. A. et al.: Indication of calcium-dependent nitric oxide synthases by sex hormones. Proc. Natl. Acad. Sci. USA 91: 5212-5216, 1994

• 4) 本庄英雄: 更年期・老年期マニュアル. 金芳堂, 京都, 1993, pp. 9-12

P.117 掲載の参考文献

• 1) Reaven, G. M.: Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988
  pubmed

• 2) DeFronzo, RA and Ferrannini, E.: Insulin resistance : amultifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atheroscle- rotic cardiovascular disease. Diabetes Care 14: 173-194, 1991

• 3) Nakamura, T., Tokunaga, K, Shimomura, I. et al.: Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107: 239-246, 1994

• 4) 中井継彦, 藤原隆一: インスリン抵抗性症候群. 治療学 29: 442-446, 1995
  Medical*Online

P.121 掲載の参考文献

• 1) 大滝英二, 住吉徹哉: ステント. Annual Reｖiew循環器1997, 杉本恒明ほか編, 中外医学社, 東京, 1997, pp. 53-61

• 2) 延吉正清: ステント. 心臓病学, 石川恭三編, 医学書院, 東京, 1995, pp. 1967-1976

P.125 掲載の参考文献

• 1) Levine, G. N., Keaney, J. F and Vita, J. A: Cholesterol reduction in cardiovascular disease. N. Engl. J. Med. 332: 512-521, 1995
  pubmed

• 2) Fielding, C. J. and Fielding, P. E.: Molecular physiology of reverse cholesterol transport J. Lipid Res. 36: 211-228, 1995
  pubmed

• 3) Lagrost, L: Regulation of cholesteryl ester transfer protein (CETP) activity: reView of in vivo and in vitro studies. Biochim. Biophys. Acta. 1215: 209-236, 1994
  pubmed

P.127 掲載の参考文献

• 1) 志水秀行, 上田敏彦, 川田志明: 突然死の実体とその病態生理, 大動脈疾患. 日内会誌87: 52-57, 1998

• 2) Borst, H. G., Walterbusch, G. and Schaps, D.: Extensive aortic replacement using“elephant trunk” prosthesis. Thorac. Cardiovasc. Surg. 31: 37, 1983

• 3) David, T. and Feindel, C. M.: An aonic valve sparing operation for patients with aortic incompetence and aneurysm of the ascending aorta. J. Thorac. Cardiovasc. Surg. 103: 617-622, 1992
  pubmed

P.129 掲載の参考文献

• 1) Dyerberg, J. and Bang, H. O.: Haemostatic function and platelet polyunsatUrated fatty acids in Eskimos. Lancet ii: 433-435, 1979

• 2) Harris, W. S.: n-3 fatty acids and serum lipoproteins: human studies. Am. J. Clin. Nutr. 65: S1645-S1654, 1997

• 3) Leaf, A. and Kang, J. X.: Prevention of cardiac sudden death by N-3 fatty acids: areview of the evidence. J. Int. Med. Res. 240: 5-12, 1996

P.131 掲載の参考文献

• 1) Herz. J. and Willnow. T. E.: Lipoprotein and receptor interaction in vivo. Curr. Opin. Lipidol. 6: 97-103, 1995
  pubmed

• 2) 繁英樹, 石川俊次, 中村治雄: レムナントリポ蛋白の意義. Medical Practice 10: 2373-2378, 1993

P.133 掲載の参考文献

• 1) 山下静也: コレステロール逆転送系と動脈硬化. 分子動脈硬化学. メディカルレビュー社, 大阪, 1995, pp. 25-37

P.135 掲載の参考文献

• 1) Vlassara, H., Bucala, R., Striker, L : Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest. 70: 138-151, 1994
  pubmed

• 2) 牧田善二: AGEと糖尿病における合併症. 糖尿病学1995. 小坂樹徳, 赤沼安夫編, 診断と治療社, 東京, 1995, pp. 209-223

• 3) Bucala, R., Makita, Z., Koschinsky, T. et al.: Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc. Natl. Acad. Sci. USA 90: 6434-6438, 1993
  pubmed

• 4) 牧田善二, 小池隆夫: 糖尿病の合併症に対する治療薬. プラクテイス13: 536-541, 1996

• 5) 渥美敏也, 牧田善二: 糖尿病合併症の分子構造とAGE (Advanced glycation end-products). Medical Practice 15: 124-125, 1998

P.137 掲載の参考文献

• 1) Yoshino, G., Hirano, T. and Kazumi, T.: Dyslipidemia in diabetes mellitUs. Diabetes Res. Clin. Pract. 33: 1-14, 1996
  pubmed

• 2) Yoshino, G., Furukawa, S. and Hirano, T.: The minimum dose of acarbose suppresses triglyceride concentration in remnant-like particles from fasted diabetic subjects. Horm. Metab. Res. 28: 329-330, 1996
  pubmed

• 3) Hirano, T., Naito, H., Kurokawa, M. et al.: High prevalence of small LDL particles in non-insulin dependent diabetic patients with nephropathy. Athero- sclerosis 123: 57-82, 1996

P.139 掲載の参考文献

• 1) American Diabetes Association : Diabetic nephropathy (position statement). Diabetes Care 21 (suppl. 1): S50-S53, 1998

• 2) Sowers, J. R and Epstein, M.: Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hy) ertension 26: 869-879, 1995

• 3) Draznin, B. and Eckel, R. H.: 糖尿病とアテローム性動脈硬化症, 星山真理 (訳), 齋藤康 (監訳), 西村書店, 新潟, 1997

P.141 掲載の参考文献

• 1) Harano, Y, Suzuki, M., Shinozaki, k et al.: Clinical impact of insulin resistance syndrome in cardiovascular diseases and its therapeutic approach. Hypertens. Res. 19 (suppl. 1): S81-S85, 1996

• 2) Sinozaki, K, Suzuki, M., Ikebuchi, M. et al.: Insulin resistance associated with compensatory hyperinsulinemia as an independed risk factor for vasospastic angina. Circulation 92: 1749-1757, 1995

• 3) Sinozaki, K, Suzuki, M., lkebuchi, M. et al.: Demon- stration of insulin resistance in coronary artery disease documented with angiography. Diabetes Care 19 (1): 1-7, 1996

P.143 掲載の参考文献

• 1) Giugliano, D., Paolisso, G. and Ceriello, A: Oxidative stress and diabetic vascular complications. Diabetes Care 19: 257-267, 1996

• 2) Semenkovich, C. F and Heinecke, J. W.: The mystery of diabetes and atherosclerosis: time for a new plot. Diabetes 46: 327-334, 1997
  pubmed

• 3) Koya, D. and King, G. L: Protein kinase C activation and the development of diabetic complications. Diabetes 47: 859-866, 1998
  pubmed

• 4) 柏木厚典, 西尾善彦, 吉川隆一: 血管内皮細胞と病態-糖尿病-. Mebio 3: 89-95, 1998

P.145 掲載の参考文献

• 1) Casey, R and Li, W. W.: Factors controlling ocular angiogenesis. Am. J. Ophthalmol. 124: 521-529, 1997

• 2) 石橋達朗, 村田敏規, 畑快右ほか: 血管内皮増殖因子 (VEGF) と糖尿病網膜症. 眼紀49: 6-10, 1998

P.147 掲載の参考文献

• 1) Tanaka, K and Sueishi, K: : lhe coagulation and fibri- nolysis systems and atherosclerosis, Lab. Invest. 69: 5-18, 1993

• 2) 中村伸: 組織因子 (Tissue Factor) 研究の新展開. 日血止誌4: 203-217, 1993

• 3) 一瀬白帝: アポリポプロテイン (a): 動脈硬化と血栓症. 日血止誌4: 363-371, 1993

• 4) Bombeli, T., Mueller, M. and Haeberli, A: Anti- coagulant properties of the vascular endothelium. Thromb. Haemost. 77: 408-423, 1997

P.149 掲載の参考文献

• 1) Ueda, M., Becker, A E., Kasayuki, N. et al.: In situ detection of platelet-derived growth factor-A and-B chain mRNA in human coronary arteries after percu- taneous translunial coronary angioplasty. Am. J. Pathol. 149: 831-843, 1996

• 2) Ohishi, M., Ueda, M., Rakugi, H. et al.: Enhanced expression of angiotensin-converting enzyme is asso- ciated with progression of coronary atherosclerosis in humans. J. Hypertens. 15: 1295-1302, 19993) Naruko, T., Ueda, M., van der Wal, A C. et al.: C-type natriuretic peptide in human coronary atherosclerotic lesions. Circulation 94: 3103-3108, 1996

• 4) Davies, M. J. and Thomas, A C. : Plaque fissuring: The case of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br. Heart J. 53: 367-373, 1985

• 5) van der Wa1, A C., Becker, A E., van der Loos, C. M. et al.: The site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89: 36- 44, 1994

P.151 掲載の参考文献

• 1) Reaven, G. M.: Role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988
  pubmed

• 2) 中村正, 徳永勝人, 松澤佑次: 内臓脂肪症候群, 最新内科学大系6: 肥満症, 臨床栄養, 井村裕夫ほか 編, 中山書店, 東京, 1995, pp. 145-151

• 3) Matsuzawa, Y.: Pathophysiology and molecular mechanisms of visceral fat syndrome: The Japanese experience. Diabetes. Metab. 」Rev. 13: 3-13, 1997

P.153 掲載の参考文献

• 1) Gotlieb, A L, Langill, B., Wong, M. K K et al.: Biology of disease. StructUre and function of the endothelial cytoskeleton. Lab. Invest. 65: 123-137, 1991

• 2) Brindle, N. P.: GroWth factors in endethelial regeneration. Ca rdiovasc. Res. 27: 1162-1172, 1993

• 3) Boor, P. J., Gotlieb, A I., Joseph, E. C. et al.: Chemica1-induced vascular injury. Toxicol. Appl. Pharmacol. 132: 177-195, 1995
  pubmed

P.155 掲載の参考文献

• 1) Stary, H. C., Chandler, A B., Glagov, A S. et al.: A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Artehosclerosis, Arnerican Heart Association. Circulation 89: 2462-2478, 1994

• 2) Langille, B. L and Ojha, M.: Blood flow dynamics, atherosclerosis and bypass graft failure. Trentls Cardiovasc. Med. 7: 111-118, 1997
  pubmed

• 3) 住吉昭信: 動脈硬化症の病理. 図説病態内科学講座, 循環器-3. 矢崎義雄ほか編, メジカルビュー社, 東京, 1993, pp. 112-125

• 4) 佐藤勇一郎, 浅田祐士郎, 住吉昭信: 平滑筋細胞. 現代医療28: 2997-3000, 1996

• 5) Hafizi, S., Chester, A H., Yacoub, M. H.: Molecular mechanisms of vascular smooth muscle cell growth. Current Opinion Cardiol. 12: 495-503, 1997

P.157 掲載の参考文献

• 1) Teramoto, T., Yamada, N., Shimano, H. et al.: Dose dependent effect of niceritrol on plasma lipoprotein- a. Scand. 1. Ctin. Lab. Invest. 56: 359-365, 1996

• 2) Blankenhorn, D. H., Nessim, SA, Johnson, RL et al.: Benefical effects of combined colestipol-niacin therapy on coronart atherosclerosis and coronary venous bypass grafts. IA. MA 257: 3233-3240, 1987

• 3) Brown, G., Albers, JJ., Fisher, LD. et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323: 1289-1298, 1990
  pubmed

P.159 掲載の参考文献

• 1) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease : the Scandinabian Simvastatin SurVival Study (4S). Lancet 344 : 1383-1389, 1994
  pubmed

• 2) Sacks, F. M., Pfeffer, M. A and Moye, L A: The effect of pracastatin on coronary events after myocardial infarction in patients with average cholesterol level. N. Engl. J. Med. 335: 1001-1009, 1996

P.163 掲載の参考文献

• 1) Loskutoff, D. J., Sawdey, M. and Mimuro, J.: Type 1 plasminogen activator inhibitor. Prog. Hemost. Thromb. 9: 87-115, 1989
  pubmed

• 2) 小川久雄: 虚血性心疾患と凝固線溶系. Athero-thrombosis 1: 26-31, 1998

P.165 掲載の参考文献

• 1) La Du, B. N.: Human serum paraoxonase/arylesterase. In: Pharmacogenetics of drugs Metabolism, ed. by Kalow, W., Pergamon Press, NY, 1992, pp. 51-91

• 2) Navab, M., Berliner, J. A, Watson, A D, et al.: The Yin and Yang of oxidation in the development of the fatty streak. Arterioscler. Thromb. Vasc. Biol. 16: 831-842, 1996
  pubmed

• 3) Mackness, M. I., Mackness, B., Durrington, P. N. et al.: Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7: 69-76, 1996
  pubmed

P.167 掲載の参考文献

• 1) Ross, R: The pathogenesis of atherosclerosis: aperspective for the 1990s. Nature 362: 801-809, 1993

• 2) Jackson, C. L.: Animal models of restenosis. Trends. Ca rdiovasc. Med. 4: 122-130, 1994

• 3) Matsuura, R, Isaka, N, Imanaka, Y. et al.: Deposition of PG-M/versican is a major cause of human coronary restenosis after percutaneous transluminal coronary angioPlasty. J. Pathol. 180: 311-316, 1996

P.169 掲載の参考文献

• 1) Gruentzig, R. A, Senning, A and Siegnthaler, W. E.: Nonoperative dilatation of coronary artery stenosis. N. Engl. J. Med. 301: 61, 1979

• 2) Nobuyoshi, M., Kimura, T., Nosaka, H. et al.: Restenosis after successful percutaneous transluminal coronary angioplasty. Serial angiographic follow up of 229 patients. J. Am. Coll. Cardiol. 12: 616, 1988
  pubmed

P.171 掲載の参考文献

• 1) Fuster, V., Badimon, L, Badimon, J. et al.: The pathogenesis of coronary artery disease and the acute coronary syndrome. N. . Engl. J. Med. 326: 242-250, 1992

• 2) Braunwald, E.: Unstable angina: a classification. Circulation 80: 410-414, 1989
  pubmed

• 3) Ambrose, J., Winters, S., Arora, R. et al.: Angiographic evolution of coronary morphology in unstable angina. J. Am. Coll. Cardiol. 7: 472-478, 1986
  pubmed

• 4) Davies, M. and Thomas, A: Plaque fissuring the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br. Heart J. 53: 363-373, 1985

• 5) The TIMI III B investigators: Effect of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Result of the TIMI III B tria1. Circulation 89: 1545, 1994

P.173 掲載の参考文献

• 1) Illingworth, D. R: Fibric acid derivatives. Drug Treatment of Hypertipidemia, ed. by Rifkind, B. M,. Marcel Dekker Inc., N Y, 1991, pp. 103-138

• 2) Ericsson, C-G., Hamsten, A, Nilsson, J. et al.: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young men postinfarction patients. Lancet 347: 849-853, 1996

P.175 掲載の参考文献

• 1) Fuster, V., Badimon, 1., Badimon, J. J. et al.: The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. J. Med. 326: 242-250, 310-318, 1992

• 2) Falk, E., Shah, P. K and Fuster, V.: Coronary plaque disruption. Circulation 92: 657-667, 1995
  pubmed

• 3) Lee, R. T. and Libby, P.: The unstable atheroma. Arten: oscler. Thromb. Vasc. Biol. 17: 1859-1867, 1997

P.177 掲載の参考文献

• 1) van der Wal, A C., Becker, A. E., van der Loos, C. M. et al.: The site of intimal ruptUre or erosion of thrombosed coronary atherosclerotic plaque is characterized by Inflammatory process irrespective of the dominant plaque morphology. Circerlation 89: 36-44, 1994
  pubmed

• 2) Naruko, T., Ueda, M., van der Wal, A C. et al.: C-type natriuretic peptide in human coronary atherosclerotic lesions. Circulation 94: 3103-3108, 1996
  pubmed

• 3) Ohishi, M., Ueda, M., Rakugi, H. et al.: Enhanced expression of angiotensin-convening enzyme is associated with progression of coronary atherosclerosis in humans. J. Hypertens. 15: 1295-1302, 1997

P.181 掲載の参考文献

• 1) Ishigami, M., Yamashita, S., Sakai, N. et al.: High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflmux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur. J. Clin. Invest. 27: 285-292, 1997
  pubmed

• 2) Tardif, J. C., Lesperance, J., Bourassa, M. et al.: Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol StUdy Group. N. Engl. J. Med. 337: 365- 372, 1997

P.185 掲載の参考文献

• 1) Komiyama, T., Shigematsu, H., Yasuhara, H. et al.: An objective assessment of intermittent claudication by nearinfrared spectroscopy. Eur. J. Vasc. Surg. 8: 294-296, 1994
  pubmed

• 2) 重松宏, 重松邦広ほか: 間欠性跛行に対する血行再建成績. 脈管学33: 265-268, 1993

• 3) Nakamura, Y, Morishita, R., Higaki, J. et al.: Hepatocyte growth factor (HGF) is a novel member of endothelium-specific growth factors: additive stimulatory effect of HGF with basic fibroblast growth factor, but not vascular endothelial growth factor. J. Hypertens. 14: 1067-1072, 1996

P.187 掲載の参考文献

• 1) Brown M. S. and Goldstein, J. L: Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Ann. Rev. Biochem. 52 : 223-261, 1983
  pubmed

• 2) Steinberg, D., Parthasarathy, S., Carew, T. E. et al.: Beyond cholesterol. Modications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320: 915-924, 1989

• 3) Chait, A and Heinecke, J. W.: Lipoprotein modification: cellular mechanisms. Curr. Opin. Lipidol. 5: 365-370, 1994
  pubmed

P.189 掲載の参考文献

• 1) Guyton, J. R and Klemp, K F.: Development of the lipid-rich core in human atherosclerosis. Arterioscler. Thromb. Vasc. Biot. 16: 4-11, 1996

• 2) Guyton, J. R: The role of lipoproteins in atherogenesis. Adv. Exp.Med. Biol. 369: 29-38, 1995
  pubmed

• 3) Yla-Herttuala, S.: Biochemistry of the arterial wall in developing atherosclerosis. Ann. N. Y. Acad. Sci. 623: 40-59, 1991
  pubmed

P.191 掲載の参考文献

• 1) McCully, K S.: Homocysteine and vascular disease. Nat. Med. 2: 386-389, 1996.
  pubmed

• 2) Morita, H., Taguchi, J., Kurihara, H. et al.: Genetic polymorphism of 5, 10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 95: 2032-2036, 1997
  pubmed

P.193 掲載の参考文献

• 1) Libby, P., Geng, Y J., Aikawa, M. et al.: Macrophages and atherosclerotic plaque stability. Curr. Opin. Lipidol. 7: 330-335, 1996
  pubmed

• 2) 枇把剛, 袴田秀樹, 堺正和ほか: 粥状硬化症における脂質と細胞増殖の関連. 血管と内皮7: 447-455, 1997

• 3) 袴田秀樹, 堀内正公: 粥状硬化の進展・退縮とマクロファージ. 血管と内皮7: 275-284, 1997

P.195 掲載の参考文献

• 1) Alberts, B., Bray, D., LeWis, J. et al. Molecular Biology of the Cell, 3rd ed., Garland Publishing, Inc., New York, 1994, pp. 787-862

• 2) Heldin, C. -H.: Simultaneous induction of stimulatory and inhibitory signals by PDGF. FEBS. Lett. 410: 17-21, 1997
  pubmed

P.197 掲載の参考文献

• 1) 中谷矩章: 二次予防研究の成績. The Lipid 4: 327- 337, 1993

• 2) Leon, A S., Myers, M. J. and Connett, J.: Leisure time physical activity and the 16-year risks of mortality from coronary heart disease and all-causes in the Multiple Risk Factor Intervention Trial (MRFIT). nt. J. Sports. Med. 18: 208-215, 1997

• 3) May, G. S., Eberlein, K A, Furberg, C. D. et al.: Secondary prevention after myocardial infarction: A review of long-term trials. Prog. Cantiovasc. Dis. 24: 331-352, 1982
  pubmed

P.201 掲載の参考文献

• 1) Gibbons, G. H. and Dzau, V. J.: The emerging concept of vascular remodeling. N. Engl. J. Med. 330: 1431-1438, 1994
  pubmed

• 2) Dzau, V. J. and Gibbons, G. H.: Vascular remodeling: mechanisms and implications. J. Cardiovasc. J. Pharmacol. 21 (supP1. 1): S1-S5, 1993

• 3) Naruko, T., Ueda, M., van der Wal, A C. et al.: C-type natriuretic peptide in human coronary atherosclerotic lesions. Circulation 94: 3103-3108, 1996
  pubmed

• 4) Ohishi, M., Ueda, M. Rakugi, H. et al.: Upregulation of angiotensin-converting enzyme during the healing process after injury at the site of percutaneous transluminal coronary angioplasty in humans. Circutation 96: 3328-3337, 1997
  pubmed

P.203 掲載の参考文献

• 1) Mehran, R., Minty, G. S., Satler, N. et al.: Treatment of in stent restenosis with excimer laser coronary angioplasty. Mechanism and results compared with PTCA Circulation 96: 2183-2189, 1997

• 2) Helms, D. R, Mehta, S., George, C. J. et al.: Excimer laser coronary angioplasty-new apProach to coronary intervention exPerience. Am. J. Cardiol. 10A (special issue): K99-K105, 1997

• 3) 水野杏一, 荒川宏編: 心血管系レーザー治療, 文光堂, 東京, 1996

• 4) Dowling, R., Petracek, M. R, Sellinger, S. L et al.: Transmyocardial revascularization with Holmium laser in patients with refractory angina who are unstable. Circulation 96: 1-247, 1997

P.205 掲載の参考文献

• 1) Cambien, E, Poirier, O., Leccerf, L. et al.: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359: 641-644, 1992

• 2) Ohishi, M., Rakugi, H. and Ogihara, T.: Association betWeen a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N. Engl. J. Med. 331: 1097-1098, 1994
  pubmed

• 3) Julier, C., Delepine M., Keamey, B. et al.: Genetic susceptibility for human familial essential hypertension in a region of homology with blood pressure link-age on rat chromosome 10. Hum. Mol. Genet. 6: 2077-2085, 1997

• 4) Sato, N., Katsuya, T., Rakugi, H. et al.: Association of variants in critical core promoter element of angiotensinogen gene with increased risk of essential hypertension. Hypertension 30: 321-325, 1997
  pubmed

• 5) Katsuya, T., Horiuchi, M., Minami, S. et al.: Genomic organization and polymorphism of human angiotensin II type 2 receptor: no evidence for its gene mutation in two families of human premature ovarian failure syndrome. Mol. Cell. Endocrinol. 127: 221-228, 1997
  pubmed

P.207 掲載の参考文献

• 1) Zhang, Y, Proenca, R, Maffei, M. et al.: Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425, 1994
  pubmed

• 2) Considine, R V., Considine, E. L, Williams, C. J. et at.: Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity. J. Clin. Invest. 95: 2986, 1995
  pubmed

• 3) Montague, C. T., Farooqi, 1. S., Whitehead, J. P. et al.: Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387: 903, 1997